Status:
COMPLETED
Effect of Dexmedetomidine and Total Intravenous Anesthesia on Endothelial Damage-Related Biomarkers
Lead Sponsor:
Firat University
Conditions:
Endothelial Damage
Dexmedetomidine
Eligibility:
All Genders
18-50 years
Phase:
PHASE4
Brief Summary
This study aimed to evaluate whether dexmedetomidine has a protective effect on endothelial damage by measuring plasma syndecan1 and heparan sulphate levels in rhinoplasty patients who take propofol+r...
Detailed Description
Endothelial Glycocalyx (EG) is a carbohydrate-rich network covering the apical surface of endothelial cells. It consists of sulphated glycoproteins linked to sialic acids (heparan sulphate, dermatan s...
Eligibility Criteria
Inclusion
- patients between the ages of 18-50 who will undergo rhinoplasty will be included in the study -
Exclusion
- patients who do not agree to participate in the study, patients with underlying peripheral arterial disease, coronary artery disease, hypertension, diabetes mellitus, and ASA (American Society of Anaesthesiologists) Classification ≥3 will be excluded.
- \-
Key Trial Info
Start Date :
April 10 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2025
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT06897696
Start Date
April 10 2025
End Date
October 31 2025
Last Update
January 6 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Firat University Hospital
Elâzığ, Turkey (Türkiye), 23100